ALS-2158 / J&J, Vertex - LARVOL DELTA

Vertex announces key 2012 business objectives as company prepares for planned global launch of KALYDECO in cystic fibrosis (Vertex) - P1 study data of ALS-2200 and ALS-2158 are expected in Q2 2012, which could enable the initiation of P2 proof-of-concept studies to evaluate multiple all-oral, interferon-free combination regimens in the H2 2012; Anticipated P4 study of INCIVEK combination therapy in African Americans with hepatitis C who were not cured with a prior treatment of pegylated-interferon & ribavirin in Q1 2012; Enrollment is expected to begin in Q1 2012 for P2b & 3b clinical studies of INCIVEK combination treatment in people who have recurrent hepatitis C following a liver transplant

Anticipated P1 data • Anticipated P2 enrollment initiation • Anticipated P3 enrollment initiation • Anticipated P4 trial • Hepatitis C Virus

Vertex, Alios start early-stage hepatitis C trials on 2 drugs (San Francisco Business Times) - Alios BioPharma & partner Vertex Pharmaceuticals said that they started two early-stage studies on separate hepatitis C drugs; Safety & tolerability studies of ALS-2200 & ALS-2158 will return data in Q2 2012

Anticipated P1 data • Hepatitis C Virus

Vertex reports fourth quarter and full-year 2011 financial results (Vertex) - Vertex announced the consolidated financial results for the fourth quarter and full-year ended December 31, 2011; Vertex expects to have on-treatment and SVR4 data from the all-oral, interferon-free arms (VX-222, INCIVEK & ribavirin) of P2 ZENITH study in the Q1 2012; Vertex expects first data from P1 study of ALS-2200 and ALS-2158 in healthy volunteers & genotype 1 pts in Q2 2012; Data from studies in other genotypes are expected later in 2012; Vertex plans to conduct P2 studies to evaluate combination regimens of ALS-2200 or ALS-2158 with INCIVEK or VX-222

Anticipated P1 data • Anticipated P2 data • Anticipated P2 trial • Financial update • Hepatitis C Virus